FR258900, a potential anti-hyperglycemic drug, binds at the allosteric site of glycogen phosphorylase

Protein Science

Volumn 16, Issue 8, 2007, Pages 1773-1782

  Tiraidis, Costas ^a   Alexacou, Kyra Melinda ^a   Zographos, Spyros E ^a   Leonidas, Demetres D ^a   Gimisis, Thanasis ^b   Oikonomakos, Nikos G ^a  

^a INSTITUTE OF BIOLOGY   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

FR258900; Glycogen phosphorylase; Inhibition; Type 2 diabetes; X ray crystallography

Indexed keywords

ADENOSINE PHOSPHATE; ANTIDIABETIC AGENT; ARGININE; FR 258900; GLYCOGEN PHOSPHORYLASE; LIGAND; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BINDING; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INHIBITION; GLYCOGEN LIVER LEVEL; GLYCOGEN SYNTHESIS; GLYCOGENOLYSIS; HYDROGEN BOND; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN INTERACTION; PROTEIN QUATERNARY STRUCTURE; PROTEIN STRUCTURE; X RAY CRYSTALLOGRAPHY;

ADENOSINE MONOPHOSPHATE; ALLOSTERIC SITE; ANIMALS; BENZAMIDES; BINDING SITES; CINNAMATES; GLUTARATES; GLYCOGEN PHOSPHORYLASE, MUSCLE FORM; HUMANS; HYPOGLYCEMIC AGENTS; LIGANDS; MODELS, MOLECULAR; PHENYLUREA COMPOUNDS; PHTHALIC ACIDS; PROTEIN CONFORMATION; RABBITS; RATS;

MUS; ORYCTOLAGUS CUNICULUS;

EID: 34547610188     PISSN: 09618368     EISSN: 1469896X     Source Type: Journal    
DOI: 10.1110/ps.072925607     Document Type: Article

References (34)

1. Anagnostou, E., Kosmopoulou, M.N., Chrysina, E.D., Leonidas, D.D., Hadjiloi, T., Tiraidis, C., Györgydeák, Z., Somsák, L., Docsa, T., Gergely, P., et al. 2006. Crystallographic studies on two bioisosteric analogues, N-acetyl-β-D-glucopyranosylamine and N-trifluoracetyl-β-D-glucopyranosylamine, potent inhibitors of muscle glycogen phosphorylase. Bioorg. Med. Chem. 14: 181-189.
2. Baker, D.J., Greenhaff, P.L., and Timmons, J.A. 2006. Glycogen phosphorylase inhibition as a therapeutic target: A review of the recent patent literature. Expert Opin. Ther. Pat. 16: 459-466.
3. Barford, D., Hu, S.-H., and Johnson, L.N. 1991. Structural mechanism for glycogen phosphorylase control by phosphorylation and AMP. J. Mol. Biol. 218: 233-260.
4. Collaborative Computational Project, Number 4. 1994. The CCP4 suite: Programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50: 760-763.
5. Furukawa, S., Tsurumi, Y., Murakami, K., Nakanishi, T., Ohsumi, K., Hashimoto, M., Nishikawa, M., Takase, S., Nakayama, O., and Hino, M. 2005a. FR258900, a novel glycogen phosphorylase inhibitor isolated from fungus No. 138354. I. Taxonomy, fermentation, isolation, and biological activities. J. Antibiot. (Tokyo) 58: 497-502.
6. Furukawa, S., Murakami, K., Nishikawa, M., Nakayama, O., and Hino, M. 2005b. FR258900, a novel glycogen phosphorylase inhibitor isolated from fungus No. 138354. II. Anti-hyperglycaemic effects in diabetic animal models. J. Antibiot. (Tokyo) 58: 503-506.
7. Hubbard, S.J. and Thornton, J.M. 1993. NACCESS, computer program. Department of Biochemistry and Molecular Biology, University College London, London, UK.
8. Johnson, L.N. 1992. Glycogen phosphorylase: Control by phosphorylation and allosteric effectors. FASEB J. 6: 2274-2282.
9. Johnson, L.N., Hajdu, J., Acharya, K.R., Stuart, D.I., McLaughlin, P.J., Oikonomakos, N.G., and Barford, D. 1989. Glycogen phosphorylase b. In Allosteric enzymes (ed. G. Herve), pp. 81-127. CRC Press, Boca Raton, FL.
10. Johnson, L.N., Martin, J.L., Acharya, K.R., Barford, D., and Oikonomakos, N.G. 1993. The refined crystal structure of the glycogen phosphorylase-glucose 6-phosphate complex. J. Mol. Biol. 232: 253-267.
11. Jones, T.A., Zou, J.Y., Cowan, S.W., and Kjeldgaard, M. 1991. Improved methods for the building of protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A 47: 110-119.
12. Klabunde, T., Wendt, U.K., Kadereit, D., Brachvogel, V., Burger, H.-J., Herling, A.W., Oikonomakos, N.G., Kosmopoulou, M.N., Schmoll, D., Sarubbi, E., et al. 2005. Acyl ureas as human liver glycogen phosphorylase inhibitors for the treatment of type 2 diabetes. J. Med. Chem. 48: 6178-6193.
13. Kraulis, P. 1991. MOLSCRIPT: A program to produce both detailed and schematic plots of protein structures. J. Appl. Crystallogr. 24: 946-950.
14. Kristiansen, M., Andersen, B., Iversen, L.F., and Westergaard, N. 2004. Identification, synthesis, and characterization of new glycogen phosphorylase inhibitors binding to the allosteric AMP site. J. Med. Chem. 47: 3537-3545.
15. Laskowski, R.A., MacArthur, M.W., Moss, D.S., and Thornton, J.M. 1993. PROCHECK - A program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 26: 283-291.
16. Leatherbarrow, R.J. 1992. GraFit, Version 3.0. Erithakus Software, Staines, UK.
17. Lu, Z., Bohn, J., Bergeron, R., Deng, Q., Ellsworth, K.P., Geissler, W.M., Harris, G., McCann, P.E., McKeever, B., Myers, R.W., et al. 2003. A new class of glycogen phosphorylase inhibitors. Bioorg. Med. Chem. Lett. 13: 4125-4128.
18. McCormack, J.C., Westergaard, N., Kristiansen, M., Brand, C.L., and Lau, J. 2001. Pharmacological approaches to inhibit endogenous glucose production as a means of anti-diabetic therapy. Curr. Pharm. Des. 7: 1451-1474.
19. Merritt, E.A. and Bacon, D.J. 1997. Raster3D: Photorealistic molecular graphics. Methods Enzymol. 277: 505-524.
20. Murshudov, G.N., Vagin, A.A., and Dodson, E.J. 1997. Refinement of macromolecular structures by the Maximum-Likelihood Method. Acta Crystallogr. D Biol. Crystallogr. 53: 240-255.
21. Ogawa, A.K., Willoughby, C.A., Bergeron, R., Ellsworth, K.P., Geissler, W.M., Myers, R.W., Yao, J., Harris, G., and Chapman, K.T. 2003. Glucose-lowering in a db/db mouse model by dihydropyridine diacid glycogen phosphorylase inhibitors. Bioorg. Med. Chem. Lett. 13: 3405-3408.
22. Oikonomakos, N.G. 2002. Glycogen phosphorylase as a molecular target for type 2 diabetes therapy. Curr. Protein Pept. Sci. 3: 561-586.
23. Oikonomakos, N.G., Melpidou, A.E., and Johnson, L.N. 1985. Crystallization of pig skeletal phosphorylase b. Purification, physical and catalytic characterization. Biochim. Biophys. Acta 832: 248-256.
24. Oikonomakos, N.G., Acharya, K.R., and Johnson, L.N. 1992. Rabbit muscle glycogen phosphorylase b: Structural basis of activation and catalysis. In Post-translational modification of proteins (eds. J.J. Harding and M.J.C. Crabbe), pp. 81-151. CRC Press, Boca Raton, FL.
25. Oikonomakos, N.G., Zographos, S.E., Johnson, L.N., Papageorgiou, A.C., and Acharya, K.R. 1995. The binding of 2-deoxy-glucose-6-phosphate to glycogen phosphorylase b: Kinetic and crystallographic studies. J. Mol. Biol. 254: 900-917.
26. Oikonomakos, N.G., Tsitsanou, K.E., Zographos, S.E., Skamnaki, V.T., Goldmann, S., and Bischoff, H. 1999. Allosteric inhibition of glycogen phosphorylase a by the potential antidiabetic drug 3-isopropyl 4-(2-chlorophenyl)-1,4-dihydro-1-ethyl-2-methyl-pyridine-3,5,6-tricarboxylate. Protein Sci. 8: 1930-1945.
27. Oikonomakos, N.G., Kosmopoulou, M.N., Chrysina, E.D., Leonidas, D.D., Kostas, I.D., Wendt, K.U., Klabunde, T., and Defossa, E. 2005. Crystallographic studies on acyl ureas, a new class of glycogen phosphorylase inhibitors, as potential antidiabetic drugs. Protein Sci. 14: 1760-1771.
28. Otwinowski, Z. and Minor, W. 1997. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276: 307-326.
29. Rath, V.L., Ammirati, M., LeMotte, P.K., Fennell, K.F., Mansour, M.N., Danley, D.E., Hynes, T.R., Schulte, G.K., Wasilko, D.J., and Pandit, J. 2000. Activation of human liver glycogen phosphorylase by alteration of the secondary structure and packing of the catalytic core. Mol. Cell 1: 139-148.
30. Sarabu, R. and Tilley, J. 2005. Recent advances in therapeutic approaches to type 2 diabetes. Annu. Rep. Med. Chem. 40: 167-181.
31. Sprang, S.R., Withers, S.G., Goldsmith, E.J., Fletterick, R.J., and Madsen, N.B. 1991. Structural basis for activation of glycogen phosphorylase b by adenosine monophosphate. Science 254: 1367-1371.
32. Treadway, J.L., Mendys, P., and Hoover, D.J. 2001. Glycogen phosphorylase inhibitors for treatment of type 2 diabetes mellitus. Expert Opin. Investig. Drugs 10: 439-454.
33. Tsitsanou, K.E., Skamnaki, V.T., and Oikonomakos, N.G. 2000. Structural basis of the synergistic inhibition of glycogen phosphorylase a by caffeine and a potential antidiabetic drug. Arch. Biochem. Biophys. 384: 245-254.
34. Zographos, S.E., Oikonomakos, N.G., Tsitsanou, K.E., Leonidas, D.D., Chrysina, E.D., Skamnaki, V.T., Bischoff, H., Goldman, S., Schram, M., Watson, K.A., et al. 1997. The structure of glycogen phosphorylase b with an alkyl-dihydropyridine-dicarboxylic acid compound, a novel and potent inhibitor. Structure 5: 1413-1425.